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We describe the geographical and temporal distri-
bution of West Nile neuroinvasive diseases (WNND) 
cases in Italy from 2008 to 2011. The increasing num-
ber of confirmed human cases from eight in 2008 to 
18 in 2009 and the occurrence of the virus in a larger 
geographical area in 2009 (moving from east to west) 
prompted the Ministry of Health to publish, in spring 
2010, a national programme for WNND human surveil-
lance, comprising veterinary and vector surveillance. 
Subsequently, in 2011, a new national plan on inte-
grated human surveillance of imported and autoch-
thonous vector-borne diseases (chikungunya, dengue 
and West Nile disease) was issued. Between 2008 
and 2011, 43 cases of WNND were reported from five 
regions in Italy with a case fatality rate of 16%. The 
incidence of WNND during the entire study period was 
0.55 per 100,000 population (range: 0.06–0.23 per 
100,000). During 2011, two new regions (Friuli-Venezia 
Giulia and Sardinia) reported confirmed cases in 
humans. Integrated human, entomological and animal 
surveillance for West Nile virus is a public health prior-
ity in Italy and will be maintained during 2012.
Introduction
West Nile Virus (WNV) infection was first identified 
in Italy in 1998, when the disease was detected in 
horses in Tuscany, with no rise in human neurological 
cases detected at the time [1]. After the WNV epidemic 
in horses in Tuscany in 2001, the Ministry of Health 
decided to implement a national veterinary surveillance 
programme. The aim of the veterinary surveillance pro-
gramme was to detect the introduction of WNV and it 
was in place in 15 Italian wetland areas, chosen due 
to the presence of a significant number of water fowl, 
including migratory bird species that can represent a 
possible risk of virus introduction [2]. The plan foresees 
Italian regions to adopt the operative procedure for 
entomological, sentinel bird and horse surveillance in 
coordination with the West Nile Disease (WND) National 
Reference Laboratory of the Public Veterinarian Health 
Department (Istituto Zooprofilattico Sperimentale) 
in Teramo, and the National Reference Laboratory for 
Vector Surveillance of the National Institute of Health 
(Istituto Superiore di Sanità, ISS) [3]. 
In summer 2005, WNV activity was detected again in 
the north-eastern part of Italy in sentinel chicken [4] 
whereas in summer 2008, WNV was confirmed in horses 
with neurological symptoms in the regions Veneto and 
Emilia-Romagna. This evidence prompted the imme-
diate implementation of a WNV surveillance plan for 
human surveillance of West Nile neuroinvasive disease 
(WNND) in the two affected regions in June 2008 [5-8]. 
During the remaining six months until November 2008, 
following the implementation of the plan, a total of 
eight human cases of WNND were reported in the two 
regions during 2008 [6,7,9]. In 2009, the number of 
human WNND cases increased to a total of 18 in that 
year and included new wet areas surrounding the Po 
river (nine cases in Emilia-Romagna, seven in Veneto 
and two in Lombardy) [5-7]. 
After the number of human cases had increased from 
eight in 2008 to 18 in 2009 and the geographical dis-
tribution WNND had widened in 2009 with the virus 
expanding from east to west, the Ministry of Health 
(MoH) published, during spring 2010, a national plan 
for WNND human surveillance in Italy that integrated 
veterinary and vector surveillance [10]. Subsequently, 
in 2011, a new national plan on integrated human sur-
veillance of imported and autochthonous vector-borne 
disease (chikungunya, dengue and West Nile disease) 2 www.eurosurveillance.org
was issued [11]. In this report we describe the geo-
graphical and temporal distribution of WNND cases in 
Italy, from 2008 to 2011. 
Methods 
The national surveillance system
The national plan for human surveillance defined 
‘affected areas‘ as provinces (secondary administra-
tive units) were laboratory-confirmed WNV infections 
in horses and/or humans had been notified in previ-
ous years or during the surveillance period (defined as 
between 15 June and 15 November, the period with the 
highest vector activity). Identification of an affected 
area immediately triggers the definition of the ‘surveil-
lance area’ that represents the regional territory of the 
affected area were the competent vector is present. 
During the surveillance period, activities to be carried 
out by local and regional health authorities are differ-
ent for affected and surveillance areas. Affected areas 
identified within the national veterinary programme 
are published every week on the IZS website [12]. 
When an affected area is defined by the veterinary 
programme, local health authorities have to activate 
an active surveillance system for WNND in workers 
employed on the farms where equine cases of WNND 
have been identified and in individuals living or work-
ing in the surrounding area (province). Moreover, 
measures for vector control have to be implemented 
immediately. At the same time, passive surveillance 
has to be set up in the surveillance area, requesting 
physicians to report all possible, probable and con-
firmed WNND cases using a modified European case 
definition [13]:
Only probable and confirmed cases have to be reported 
to the national level (MoH and ISS). A possible case is 
defined as any person meeting the clinical criteria of 
(fever ≥38,5° C, and at least one of the following: viral 
encephalitis, viral meningitis, polyradiculoneuritis 
(a condition similar to Guillain–Barré syndrome), and 
acute flaccid paralysis. A case is considered probable if 
the patient meets the clinical criteria, and their serum 
sample shows either a WNV-specific antibody response 
(IgG or IgM) with seroconversion from negative to posi-
tive or a four-fold increase in the seroconversion titre on 
two subsequent samples. A confirmed case is defined 
as any person meeting the clinical criteria and at least 
one of the following four laboratory criteria: (i) isola-
tion of WNV from blood or cerebrospinal fluid (CSF), 
(ii) presence of IgM antibodies in the CSF detected by 
ELISA, (iii) detection of WNV RNA by RT-PCR in blood or 
CSF, or (iv) a specific antibody response (IgG or IgM) 
against WNV detected by neutralisation assay.
All possible cases have to be notified by the regional 
authorities to the MoH and to the ISS (National Centre 
for Epidemiology, Surveillance and Health Promotion) 
using a specific Internet-based software that is 
password-protected. The system permits the local or 
regional health authorities to introduce possible cases 
directly on the website and to update the entry when 
more information from diagnostic tests becomes avail-
able. The regional reference laboratory (or the hospital 
laboratory) has to confirm the case through isolation of 
WNV from blood or CSF, detection of IgM antibodies in 
CSF by ELISA, detection of WNV RNA by RT-PCR in blood 
or CSF, or by neutralisation test if a specific IgG or IgM 
antibody response was detected in the serum sample. 
In case a neutralisation test is not available at the local 
or regional level, patient sera should be sent to the 
National Reference Laboratory at ISS that will perform 
the neutralisation test for confirmation.
Moreover, if in the same year human cases of WNND 
are detected, immediate WNV nucleic acid amplifica-
tion test (NAAT) screening of all blood and haematopoi-
etic stem cells donations are introduced in affected 
areas (provinces), and in surveillance areas (regions) 
additional screening of solid organ donations, accord-
ing to the blood directive [14,15]. At the national level, 
all blood, tissue and solid organ donors who travelled 
Table 1
Distribution of cases of West Nile neuroinvasive disease by region and year, Italy, 2008–11 (n=43)
Region Provinces of exposure 2008 2009 2010 2011 Totala
Emilia-Romagna Ferrara, Bologna, Modena 3 9 0 [+1b] 0 12
Veneto c  Belluno, Padua, Rovigo,  
Treviso, Venice, Vicenza 5 7 3 [+1b] 8 23c 
Lombardy Mantua 0 2 0 0 2
Friuli-Venezia Giulia Udine 0 0 0 2 2
Sardinia  Oristano, Olbia 0 0 0 4 4
Totala  8 18 3 14 43
a   Not including imported cases. 
b  Both cases imported from Romania.
c   These cases do not include West Nile fever cases identified within the regional surveillance system in the Veneto region that have been 
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to an affected area have to be temporarily deferred for 
28 days starting with the day they left the affected 
area [14].
In our analysis we did not include imported WNND 
cases notified in the regions Veneto and Emilia-
Romagna, cases detected in organ donors [16], and 
West Nile fever cases identified within the regional 
surveillance system for WNV fever in the Veneto region. 
Those cases have already been reported and described 
in [8].
Data analysis
Incidence rates were calculated using the National 
Bureau of Statistics estimates of the Italian popula-
tion for 2010 (mid-year) [17]. Comparison of categorical 
variables was assessed using the chi-square test. The 
analysis was carried out using STATA (Version 11). 
Results 
From June 2008 to November 2011, 43 confirmed 
WNND cases were notified in Italy. The distribution   
of WNND cases by year and region is reported in Table 
1. All cases described in the present report were con-
firmed cases.
All 43 cases reported not to have travelled abroad dur-
ing the incubation period. However, two additional 
cases that occurred in 2010, one in the Emilia-Romagna 
and one in the Veneto region, reported to have trav-
elled in Romania during the incubation period (within 
15 days before the disease onset). Furthermore, a prob-
able WNND case reported in 2011 in the Toscana region 
had IgM and IgG antibodies against Toscana virus 
(confirmed by neutralisation test), indicating acute 
disease, as well as IgG antibodies against WNV (con-
firmed by neutralisation test), suggesting a previous 
exposure to WNV. This patient was an immigrant from 
India and was therefore considered as an imported 
case. Notably, one case in 2009 and four cases in 2011 
were reported in organ recipients who received organs 
from two donors resident in affected areas [15]. In our 
study data from the three imported cases and from the 
two donors and organ recipients are not included.
The median age of the 43 cases was 70 years (range: 
33–88 years) during the entire study period, varying 
from 71.6 (range: 50–86 years) in 2008 to 72.2 (range: 
49–84 years) in 2009, 46.5 (range: 29–68 years) in 
2010 and 68.8 (range: 33–88 years) in 2011. The attack 
rate increased significantly with age (p=0.0001) and 
the proportion of males was significantly higher than 
of females (p=0.014). None of the patients were vac-
cinated against yellow fever, tick-borne encephalitis 
or Japanese encephalitis. For 30 of 43 cases follow-up 
information was available and 25 of 43 recovered.
The trend over time of human cases of neuroinvasive 
WNV infection by month of symptom onset and the 
geographical location of cases from 2008 to 2011 is 
shown in Figures 1 and 2. September was the peak 
month in all years but 2009 when the peak was in 
August. The majority of WNND cases were reported 
from the provinces Ferrara, Treviso and Rovigo (Table 
2). During 2011, two new regions (Friuli-Venezia Giulia 
and Sardinia) reported confirmed cases in horses, and 
later confirmed cases of WNND in humans. 
All WNND cases were hospitalised. Seven of them 
(three in 2009 and four in 2011) died during hospitali-
sation, corresponding to a case fatality rate of seven 
of the 43 WNND cases (16%). The median age of WNND 
cases who died was 76 years (range: 72–82 years) in 
2009, 70 years (range: 34–87 years) in 2011 and 73 
years (range: 34–87 years) overall. The reported fatali-
ties do not consider the two donors resident in the 
affected areas.
Discussion
Overall from 2008 to 2011, 43 confirmed autochtho-
nous cases of WNND were reported in Italy. In this 
report we focus on WNND cases that conformed with 
the case definition of the Italian National Surveillance 
system. From 2008 to 2009, the incidence of West Nile 
disease increased two-fold and most of the affected 
areas were localised in north-eastern Italy, with the 
disease apparently moving from east to west. In 2010, 
the incidence rate decreased four-fold and cases were 
mostly localised in north-eastern Italy. It increased 
again three-fold in 2011, when cases occurred in the 
same provinces as in previous years and also in new 
regions. In fact, a new geographic pattern of WNV 
spread was observed in 2011, with a southward expan-
sion that affected areas in the region Sardinia. During 
the entire study period, most of the areas affected by 
WNV were localised in north-eastern Italy, with the 
highest incidence rate (2.43 per 100,000) observed in 
Figure 1
Cases of West Nile neuroinvasive disease by month of 
onset, Italy, 2008–11 (n=43)
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the Rovigo province in the Veneto region, a very humid 
and flat area limited by the rivers Po and Adige. In 
2011, the highest incidence rate (1.80 per 100,000) was 
observed in a newly affected area, Oristano province in 
the Sardinia region.
We found a case fatality rate of 16% during the entire 
study period (2008–11) that was higher than in Israel 
(8.4% in 2000 and 8% in the surveillance period 2005–
10), Romania (4.3% in 1996) [18-20] and the United 
States (9% in the surveillance period 1999–08) [21], 
and similar to that described Greece (17% in 2010) [22]. 
In Italy, as described for Greece [22], an association 
between age and severe disease was observed. 
During the study period, veterinary and human sur-
veillance activities were intensified across the country 
[2,23] in order to define a system able to detect WNV cir-
culation as early as possible in infected animals for trig-
gering immediate surveillance of WNND in humans. The 
calculation of incidence and case fatality rate of WNND 
cases in humans may be affected by underreporting 
due to inappropriate use of the case definition at the 
regional level or due to under-reporting of cases who 
attend healthcare services but whose disease status is 
incorrectly diagnosed. However, since the case defini-
tion of human cases includes only WNND, it is unlikely 
that the clinical picture should be affected by underre-
porting and under-ascertainment (if also the case defi-
nition for West Nile fever was included in the National 
Surveillance System, a high degree of underreporting 
of clinical cases would be likely). 
Notably, as far as we are aware, only WNV lineage 1 
infections have been described in Italy since 2008, but 
the situation changed in 2011. Recently in 2011, co-cir-
culation of both lineage 1 and 2 (the latter very closely 
related to the Hungarian lineage) has been demon-
strated in north-east Italy [24], suggesting a probable 
introduction of lineage 2 in the southern European 
countries possibly along the routes of migratory birds 
[24,25]. However, as yet no human cases infected with 
WNV lineage 2 have been detected in the north-east-
ern affected areas of Italy. As a consequence, it can be 
2008 (n=8 cases; n=5 provinces)
2010 (n=3 cases; n=2 provinces) 2011 (n=14 cases; n=6 provinces)
2009 (n=18 cases; n=7 provinces)
Figure 2
Provinces with confirmed human cases of West Nile neuroinvasive disease, Italy, 2008–11 (n=43)5 www.eurosurveillance.org
expected that both lineages will be co-circulating in 
these areas in the next season probably. However it is 
impossible to predict if this will enhance or reduce the 
virulence of the virus in humans, should genetic recom-
bination occur [26]. Moreover, genomic sequencing of 
the virus isolate from one of the four cases confirmed 
in Sardinia (Olbia province) showed that the virus 
belonged to WNV lineage 2 (unpublished data), simi-
lar to that circulating in Greece in 2010 (Dr Loredana 
Nicoletti, personal communication, Jan 2012). Another 
lineage 2 virus was isolated from a case of West Nile 
fever that was described in the Marche region (Ancona 
province) [27]. The case was a man in his late 50s pre-
senting with high fever and without evidence of neu-
roinvasive disease. For this reason he was not included 
in the present analysis. The genomic sequencing of 
that isolate showed that the virus belonged to WNV lin-
eage 2 and had 99% identity to the complete genome 
of isolate goshawk-Hungary/04 and to the more recent 
Nea Santa-Greece-2010 isolate [28].
The confirmed cases from the Sardinia and Marche 
regions who were infected with WNV lineage 2, where 
diagnosed by detection of WNV RNA both in serum 
or plasma and in urine [27]. As previously reported, 
urine samples are more appropriate for WNV diagnosis 
because of longer shedding and higher viral load in 
the kidneys [29], which was also shown in experimen-
tal animal studies [30]. In fact, serum or plasma may 
give false-negative results due to the short duration of 
viraemia, while WNV can be shed in urine even years 
after the initial infection [29]. However, the use of the 
WNV RNA in urine is still debated [31]. 
In 2011, many autochthonous WNV human cases were 
reported in Europe and in neighbouring countries: 96 
confirmed human cases in the European Union (69 in 
Greece, three in Hungary, 14 in Italy and 10 in Romania), 
and 207 in neighbouring countries (two in Albania, four 
in the Former Yugoslav Republic of Macedonia, 34 in 
Israel, 153 in the Russian Federation, three in Tunisia, 
three in Turkey and eight in Ukraine) [32].
In 2012, integrated human, entomological and ani-
mal surveillance will be continued in Italy in order to 
monitor the spread of WNV and to implement control 
measures for blood transfusions and organ donations, 
in accordance with the Blood Directive [33], to control 
and prevent transmission of the disease in humans. 
Comprehensive epidemiological, virological and ento-
mological investigations are crucial for a better under-
standing of factors triggering the spread of WNV. In 
Table 2
Characteristics of reported West Nile neuroinvasive disease, Italy, 2008–11 (n=43)
Characteristics Number of cases (incidence ratea/100,000)
Age group (years 2008 2009 2010 2011 Total
<30 0 (0) 0 (0) 0 (0)  0 (0) 0 (0)
30–49 0 (0)  1 (0.04) 2 (0.09) 3 (0.13) 6 (0.27)
50–59 2 (0.21) 0 (0) 0 (0) 0 (0) 2 (0.21)
60–69 1 (0.12) 4 (0.46) 1 (0.12) 2 (0.23) 8 (0.93)
≥70 5 (0.44) 13 (1.15) 0 (0)  9 (0.79) 27 (2.38)
Sex
Female 3 (0.08) 5 (0.13) 1 (0.03) 5 (0.13) 14 (0.35)
Male 5 (0.13) 13 (0.34) 2 (0.05) 9 (0.24) 29 (0.77)
Province (region) of residence
Ferrara (Emilia-Romagna) 2 (0.56) 5 (1.39) 0 (0) 0 (0) 7 (1.95)
Bologna (Emilia-Romagna) 1 (0.10) 2 (0.20) 0 (0) 0 (0) 3 (0.30)
Modena (Emilia-Romagna) 0 (0) 2 (0.29) 0 (0) 0 (0) 2 (0.29)
Belluno (Veneto) 0 (0) 0 (0) 0 (0) 1 (0.47) 1 (0.47)
Venice (Veneto) 1 (0.12) 1 (0.12) 2 (0.23)  1 (0.12) 5 (0.58)
Vicenza (Veneto) 3 (0.35) 0 (0) 1 (0.12) 0 (0) 4 (0.46)
Treviso (Veneto) 0 (0) 1 (0.11) 0 (0) 6 (0.68) 7 (0.79)
Rovigo (Veneto) 1 (0.40) 5 (2.02)  0 (0) 0 (0) 6 (2.43)
Olbia (Sardinia) 0 (0) 0 (0) 0 (0) 1 (0.64) 1 (0.64)
Oristano (Sardinia) 0 (0) 0 (0) 0 (0) 3 (1.80) 3 (1.80)
Udine (Friuli-Venezia Giulia) 0 (0) 0 (0) 0 (0) 2 (0.37) 2 (0.37)
Mantua (Lombardy) 0 (0) 2 (0.48) 0 (0) 0 (0) 2 (0.48)
Total 8 (0.10) 18 (0.23) 3 (0.06) 14 (0.18) 43 (0.55)
a   Incidence rates were calculated using the 2010 mid-year population of the affected areas (provinces) and respective groups as denominator, 
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Italy, public health authorities (both veterinarian and 
human) should improve their collaboration at national, 
regional and local levels. 
Establishing and having in place such an integrated 
surveillance could also be valuable to rapidly identify 
the risk of introduction of new vector-borne diseases 
with zoonotic potential, the most obvious candidates 
being chikungunya [34] and dengue fever [35], not to 
forget Malaria [36].
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